Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
To observe the efficacy of apatinib combined with AI regimen chemotherapy compared with AI
regimen chemotherapy and single-agent apatinib in patients with unresectable soft tissue
sarcoma. The main observations were progression-free survival (PFS) and progression-free
control rate (PFR), followed by objective response rates (ORR, CR+PR), disease control rate
(DCR, CR+PR+SD), and overall survival ( OS).
To observe the safety of apatinib combined with AI chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital